StoneX Group’s Aldeyra Therapeutics ALDX Stock Holding History

StoneX Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.1K	Buy	+19,296	New	+$33.2K	﹤0.01%	1265

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

StoneX Group's ALDX Position: Q2 2026 in Review

StoneX Group opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 19,296 shares worth $33.1K. The stake represents ﹤0.01% of the portfolio and ranks #1265 among its holdings.

108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

StoneX Group held 19,296 shares of Aldeyra Therapeutics worth $33.1K as of Q2 2026.
Aldeyra Therapeutics was a new StoneX Group position in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1265 holding.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.